6:29 PM
Oct 01, 2012
 |  BC Extra  |  Top Story

Astellas, J&J in autoimmune deal

Astellas Pharma Inc. (Tokyo:4503) granted Johnson & Johnson (NYSE:JNJ) exclusive, worldwide rights, excluding Japan, to develop and commercialize autoimmune product ASP015K....

Read the full 99 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >